Rohan Vemu

Also affiliated with Baylor College of Medicine, Methodist Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in TH-MYCN mice”.

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in TH-MYCN mice

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.09.447746

N/A

0DataRank · unranked

1 citations

Spyridon Karageorgos, George D. Ferry, Adam J. Wolpaw, Chakkapong Burudpakdee, Priya Khurana +5 more

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy

OncoImmunology(2022)10.1080/2162402x.2022.2075204

N/A

0DataRank · unranked

22 citations

Spyridon Karageorgos, GM Ferry, AJ Wolpaw, Chakkapong Burudpakdee, Priya Khurana +6 more

High-dose DFMO alters protein translation in neuroblastoma

Neoplasia(2025)10.1016/j.neo.2025.101215

N/A

0DataRank · unranked

3 citations

Kangning Liu, Rohan Vemu, Elizabeth W. Scadden, Yimei Li, Annette Vu +2 more